1. France Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Guerbet SA

Guerbet SA

5.90
EUR
+0.09
(+1.55%)
336.51MMarket Cap
Mar 24Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
32.01
33.54
40.09
62.4
64.56
63.18
65.06
56.88
58.33
60.99
62.94
67.53
63.31
- -
Basic EPS, GAAP
1.68
2.14
3.21
2.33
3.69
3.72
2.97
1.45
2.59
-3.26
1.89
1.28
-8.59
- -
Free Cash Flow per Basic Share
1.85
2.36
2.4
-0.89
0.76
2.62
0.28
4.82
5.31
-1.59
-2.1
1.92
3.53
- -
Dividend per Share
0.5
0.5
0.5
0.64
0.86
0.85
0.85
0.7
0.7
0.85
0.5
0.5
- -
- -
Book Value per Share
19.56
21.26
22.92
25.22
27.28
29.28
30.93
29.21
32.08
30.08
30.08
31.28
21.16
31.28
Tangible Book Value per Share
16.59
17.69
15.46
16.72
18.62
14.72
15.85
14.26
17.14
22.32
22.36
22.82
16.29
22.82
Basic Weighted Avg Shares
12
12
12
12
13
13
13
13
13
13
13
13
13
13
Sales/Revenue/Turnover
391
409
490
776
809
795
819
717
736
769
796
851
799
- -
Operating Margin (%)
7.69
9.57
12.25
7.21
10.02
8.32
6.32
5.97
5.36
5.58
4.92
5.73
1.01
- -
Depreciation Expense
24
25
29
49
43
42
59
58
58
123
58
73
162
- -
Net Income, GAAP
20
26
39
29
46
47
37
18
33
-41
24
16
-108
- -
Effective Tax Rate (%)
26.06
27.93
35.6
38.53
30.82
29.53
27.1
18.02
- -
- -
28.03
30.39
- -
- -
Profit Margin (%)
5.25
6.38
8.01
3.73
5.72
5.89
4.56
2.55
4.43
-5.34
3
1.89
-13.56
- -
Working Capital
88
90
243
296
295
157
299
268
259
270
352
335
359
335
LT Debt
62
45
301
331
287
193
341
318
300
278
374
351
392
351
Total Equity
238
259
282
315
342
367
389
368
405
380
378
392
260
392
Return on Invested Capital (%)
6.45
8.04
7.56
4.82
7.44
6.42
4.79
4.59
- -
- -
3.71
4.31
- -
- -
Return on Capital (%)
6.37
8
8.29
4.96
7.19
7.3
5.46
2.99
- -
- -
4.56
4.25
- -
- -
Return on Common Equity (%)
8.82
10.51
14.49
9.69
14.07
13.21
9.88
4.82
8.45
-10.48
6.3
4.16
-32.77
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
13
27
44
LT Borrowings
361
362
338
LT Finance Leases
14
14
13
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
13
Market Capitalization
245
443
337

Working Capital

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
582
604
590
Cash, Cash Equivalents & STI
93
96
86
Accounts Receivable, Net
150
172
173
Inventories
305
326
301
Total Current Liabilities
229
240
254
Payables & Accruals
- -
- -
- -
ST Debt
13
27
44
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.14%
-5.31%
-33.58%
Free Cash Flow
128.85%
-38.91%
83.6%
Net Income, GAAP
-114.78%
-222.25%
-773.53%
Sales/Revenue/Turnover
6.29%
2.29%
-6.16%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
796
2024
- -
- -
851
2025
- -
- -
799

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1.89
2024
- -
- -
1.28
2025
- -
- -
-8.59

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.5
2024
- -
- -
0.5
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Karim Boussebaa
Full Time Employees
2,746
Sector
Health technology
Industry
Medical specialties
Address
15, rue des Vanesses Paris IF France 93420
IPO Date
Jan 15, 1986
Website
guerbet.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Guerbet S.A. Guerbet SA develops, manufactures and markets contrast agents, delivery systems, medical devices and related solutions for diagnostic and interventional medical imaging, including X-ray imaging products such as Xenetix, Optiray, Oxilan and Telebrix; MRI products such as Dotarem; and other contrast products for echography, nuclear medicine and fine chemicals, along with brands including Lipiodol, Endorem, Artirem and Lumirem. The company operates production sites in France, the United States, Ireland and Brazil, with Europe accounting for 37% of net sales; it targets healthcare providers in diagnostic imaging (MRI and CT) and interventional radiology segments worldwide. Founded in 1926 and headquartered at 15 rue des Vanesses, Zone Paris Nord II, Villepinte, France, Guerbet recently formed a strategic partnership with Nuclidium on May 22, 2024, to develop targeted copper-based radiopharmaceuticals, sold assets including the SeQure and DraKon microcatheters to Argon Medical in January 2025 to expand its oncology portfolio, reported revenue of €851 million in 2024 with return to growth in Q3 2025, and announced a change in general management while confirming full-year financial targets.